Saturday, 31 October 2026European Markets

EURASIA FONC INV Stock Is 19% Up In The Last 5 Sessions

Loading stream...

(vianews) - shares of eurasia fonc inv (cac 40: efi.pa) rose by a staggering 19.21% in 5 sessions from €0.3 to €0.36 at 14:56 est on thursday, following the last session's downward trend. cac 40 is jumping 0.79% to €7,391.02, after four sequential sessions in a row of gains.

about eurasia fonc inv

eurasia fonciere investissements société anonyme owns, develops, and manages corporate and commercial real estate assets. the company was formerly known as mb retail europe and changed its name to eurasia fonciere investissements société anonyme in january 2012. the company was founded in 1984 and is headquartered in paris, france. eurasia fonciere investissements société anonyme is a subsidiary of eurasia groupe sa.

volatility

eurasia fonc inv's last week, last month's, and last quarter's current intraday variation average was 18.54%, 0.07%, and 14.54%.

eurasia fonc inv's highest amplitude of average volatility was 18.54% (last week), 13.86% (last month), and 14.54% (last quarter).

volume

today's last reported volume for eurasia fonc inv is 2 which is 96.96% below its average volume of 66.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, eurasia fonc inv's stock is considered to be oversold (<=20).

more news about eurasia fonc inv (efi.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com